相似文献
1
Alpha-fetoprotein specific CD4 and CD8 T cell responses in patients with hepatocellular carcinoma.
World J Hepatol. 2010 Jul 27;2(7):256-60. doi: 10.4254/wjh.v2.i7.256.
2
Lack of ex vivo peripheral and intrahepatic α-fetoprotein-specific CD4+ responses in hepatocellular carcinoma.
Int J Cancer. 2011 Nov 1;129(9):2171-82. doi: 10.1002/ijc.25866. Epub 2011 Mar 25.
3
Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization.
J Immunol. 2007 Feb 1;178(3):1914-22. doi: 10.4049/jimmunol.178.3.1914.
4
Comprehensive analysis of the alpha-fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinoma.
Hepatology. 2008 Dec;48(6):1821-33. doi: 10.1002/hep.22535.
5
alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
Hum Immunol. 2007 May;68(5):334-41. doi: 10.1016/j.humimm.2007.01.008. Epub 2007 Feb 21.
6
Route of antigen delivery impacts the immunostimulatory activity of dendritic cell-based vaccines for hepatocellular carcinoma.
J Immunother Cancer. 2015 Jul 21;3:32. doi: 10.1186/s40425-015-0077-x. eCollection 2015.
7
AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patients.
J Immunother. 2007 May-Jun;30(4):425-37. doi: 10.1097/CJI.0b013e31802fd8e2.
8
Expansion of anti-AFP Th1 and Tc1 responses in hepatocellular carcinoma occur in different stages of disease.
Br J Cancer. 2010 Feb 16;102(4):748-53. doi: 10.1038/sj.bjc.6605526. Epub 2010 Jan 19.
9
Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma.
Hepatology. 2011 Apr;53(4):1206-16. doi: 10.1002/hep.24149.
10
Identification of alpha-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma.
Int J Cancer. 2006 Mar 1;118(5):1194-204. doi: 10.1002/ijc.21468.
引用本文的文献
1
ZNF765 is a prognostic biomarker of hepatocellular carcinoma associated with cell cycle, immune infiltration, mA modification, and drug susceptibility.
Aging (Albany NY). 2023 Jul 4;15(13):6179-6211. doi: 10.18632/aging.204827.
2
Deciphering and Reversing Immunosuppressive Cells in the Treatment of Hepatocellular Carcinoma.
J Liver Cancer. 2020 Mar;20(1):1-16. doi: 10.17998/jlc.20.1.1. Epub 2020 Mar 31.
3
Molecular mechanisms of circular RNAs, transforming growth factor-β, and long noncoding RNAs in hepatocellular carcinoma.
Cancer Med. 2019 Nov;8(15):6684-6699. doi: 10.1002/cam4.2553. Epub 2019 Sep 15.
4
Alarmin augments the antitumor immunity of lentiviral vaccine in ectopic, orthotopic and autochthonous hepatocellular carcinoma mice.
Theranostics. 2019 May 31;9(14):4006-4018. doi: 10.7150/thno.32720. eCollection 2019.
5
Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma.
Immunotherapy. 2016;8(3):299-313. doi: 10.2217/imt.15.126. Epub 2016 Feb 11.
6
Route of antigen delivery impacts the immunostimulatory activity of dendritic cell-based vaccines for hepatocellular carcinoma.
J Immunother Cancer. 2015 Jul 21;3:32. doi: 10.1186/s40425-015-0077-x. eCollection 2015.
7
Impaired function of CD4+ T follicular helper (Tfh) cells associated with hepatocellular carcinoma progression.
PLoS One. 2015 Feb 17;10(2):e0117458. doi: 10.1371/journal.pone.0117458. eCollection 2015.
8
Correlation analysis of peripheral blood T cell subgroups, immunoglobulin and prognosis of early hepatocellular carcinoma after hepatectomy.
Int J Clin Exp Med. 2014 Nov 15;7(11):4282-90. eCollection 2014.
9
Tumor-derived α-fetoprotein impairs the differentiation and T cell stimulatory activity of human dendritic cells.
J Immunol. 2014 Dec 1;193(11):5723-32. doi: 10.4049/jimmunol.1400725. Epub 2014 Oct 29.
10
Cellular immune suppressor mechanisms in patients with hepatocellular carcinoma.
Dig Dis. 2012;30(5):477-82. doi: 10.1159/000341695. Epub 2012 Oct 24.
本文引用的文献
1
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80. doi: 10.1073/pnas.1003345107. Epub 2010 Apr 12.
2
Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC.
J Immunother. 2010 Feb-Mar;33(2):211-8. doi: 10.1097/CJI.0b013e3181bb499f.
3
Expansion of anti-AFP Th1 and Tc1 responses in hepatocellular carcinoma occur in different stages of disease.
Br J Cancer. 2010 Feb 16;102(4):748-53. doi: 10.1038/sj.bjc.6605526. Epub 2010 Jan 19.
4
Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma.
J Gastroenterol. 2010 Apr;45(4):451-8. doi: 10.1007/s00535-009-0155-2. Epub 2009 Nov 20.
5
Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma.
Gastroenterology. 2009 Aug;137(2):682-90. doi: 10.1053/j.gastro.2009.04.045. Epub 2009 Apr 23.
6
Comprehensive analysis of the alpha-fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinoma.
Hepatology. 2008 Dec;48(6):1821-33. doi: 10.1002/hep.22535.
7
A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.
Hepatology. 2009 Jan;49(1):124-32. doi: 10.1002/hep.22626.
8
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.
N Engl J Med. 2008 Jun 19;358(25):2698-703. doi: 10.1056/NEJMoa0800251.
9
TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis.
Cancer Cell. 2008 Jun;13(6):507-18. doi: 10.1016/j.ccr.2008.04.001.
10
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells.
Gastroenterology. 2008 Jul;135(1):234-43. doi: 10.1053/j.gastro.2008.03.020. Epub 2008 Mar 21.
Zotero 插件